BUFFALO, NY--(Marketwire - April 30, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that an interview with Rachel Levine, Director of Corporate Development and Communications, has been posted to www.corporateprofile.com.
Cleveland BioLabs is developing a pipeline of products for multiple defense and medical applications from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.
In the interview, Levine discusses CBLI’s lead compound, CBLB502, which is being developed under the U.S. Food and Drug Administration’s Animal Efficacy Rule to treat Acute Radiation Syndrome or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon, or from a nuclear accident. CBLB502 is also being developed as a supportive care measure to reduce and prevent occurrence of side effects of radiotherapy or chemotherapy in cancer treatment.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company’s website at http://www.cbiolabs.com.
About Corporate Profile.com
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in a unique platform for investors to receive today’s hottest tips and market info.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s periodic filings with the Securities and Exchange Commission.
Contact:
Rachel Levine, Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com
